| Date Filed | Type | Description |
| 09/03/2021 |
REVOKED
| Form REVOKED - Commission order revoking Exchange Act registration [Section 12(j)]: |
| 01/27/2021 |
SC 13G/A
| EMA Financial, LLC reports a 9.9% stake in CEREBAIN BIOTECH CORP |
| 02/13/2020 |
SC 13G/A
| EMA Financial, LLC reports a 9.9% stake in CEREBAIN BIOTECH CORP |
| 10/01/2019 |
NT 10-K
| Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405: |
| 07/23/2019 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 05/20/2019 |
10-Q
| Quarterly Report for the period ended March 31, 2019 |
| 05/16/2019 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB: |
| 04/22/2019 |
DEF 14C
| Form DEF 14C - Other definitive information statements: |
| 04/05/2019 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...|
Docs:
|
"Form Certificate of Designation",
"Form of 12% Convertible Promissory Note issued March 15, 2019, to Auctus Fund, LLC",
"Form of Securities Purchase Agreement dated March 15, 2019, by and between Cerebain Biotech Corp. and Auctus Fund, LLC",
"Form of Common Stock Purchase Warrant dated March 1, 2019, issued to Auctus Fund LLC",
"Form of Common Stock Purchase Warrant dated March 1, 2019, issued to Crown Bridge Partners, LLC",
"Form of Amendment to the Convertible Promissory Note issued March 26, 2019, to Auctus Fund LLC",
"Form of Amendment to the Convertible Promissory Note issued February 14, 2018, to Crown Bridge Partners, LLC" |
|
| 04/05/2019 |
PRE 14C
| Form PRE 14C - Other preliminary information statements: |
| 02/19/2019 |
10-Q
| Quarterly Report for the period ended December 31, 2018 |
| 02/15/2019 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB: |
| 02/14/2019 |
SC 13G
| EMA Financial, LLC reports a 9.9% stake in CEREBAIN BIOTECH CORP |
| 12/26/2018 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits |
| 11/14/2018 |
10-Q
| Quarterly Report for the period ended September 30, 2018 |
| 09/26/2018 |
10-K
| Annual Report for the period ended June 30, 2018 |
| 09/25/2018 |
4
| CLEMONS ERIC (President) has filed a Form 4 on CEREBAIN BIOTECH CORP.|
Txns:
| Granted 160,000 shares
@ $0.18, valued at
$28.8k
|
|
| 09/25/2018 |
4
| Tate Wesley D. (CFO) has filed a Form 4 on CEREBAIN BIOTECH CORP.|
Txns:
| Granted 160,000 shares
@ $0.18, valued at
$28.8k
|
|
| 05/15/2018 |
10-Q
| Quarterly Report for the period ended March 31, 2018 |
| 02/06/2018 |
10-Q
| Quarterly Report for the period ended December 31, 2017 |
| 11/09/2017 |
10-Q
| Quarterly Report for the period ended September 30, 2017 |
| 09/15/2017 |
10-K
| Annual Report for the period ended June 30, 2017 |
| 08/04/2017 |
8-K
| Quarterly results |
| 05/11/2017 |
10-Q
| Quarterly Report for the period ended March 31, 2017 |
| 02/10/2017 |
10-Q
| Quarterly Report for the period ended December 31, 2016 |
| 11/14/2016 |
10-Q
| Quarterly Report for the period ended September 30, 2016 |
| 09/27/2016 |
10-K
| Annual Report for the period ended June 30, 2016 |
| 06/16/2016 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
| 06/15/2016 |
4
| Tate Wesley D. (CFO) has filed a Form 4 on CEREBAIN BIOTECH CORP.|
Txns:
| Granted 150,000 shares
@ $0.27, valued at
$40.5k
Granted 150,000 shares
@ $0.3, valued at
$45k
|
|
| 05/16/2016 |
10-Q
| Quarterly Report for the period ended March 31, 2016 |
| 04/22/2016 |
8-K
| Form 8-K - Current report |
| 02/22/2016 |
10-Q
| Quarterly Report for the period ended December 31, 2015 |
| 02/22/2016 |
10-K/A
| Annual Report for the period ended June 30, 2015 [amend] |
| 11/16/2015 |
10-Q
| Quarterly Report for the period ended September 30, 2015 |
|